Generic Name: cabotegravir + rilpivirine

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Single-Tablet Regimens

Company: ViiV Healthcare and Janssen Therapeutics

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Cabenuva (cabotegravir + rilpivirine), a long-acting injectable regimen, is being studied as a treatment for HIV. It has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.


General Info

Cabenuva (cabotegravir + rilpivirine) is an experimental HIV medication. It contains two different types of HIV drugs: the experimental integrase inhibitor cabotegravir and an injectable version of rilpivirine (sold in pill form as Edurant). It is currently in Phase III clinical trials.


Dosage

Dosing Info:

This is a long-acting injectable regimen administered every four weeks.


Side Effects

N/A


Other Info

https://www.poz.com/article/viiv-applies-approval-first-longacting-injectable-hiv-regimen


For More Info: https://www.cabenuvahcp.com/

Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/

Last Reviewed: October 11, 2019